Contraindications: Hypersensitivity to fluconazole. Concomitant administration of QT-prolonging medications (e.g., erythromycin, pimozide).
Cautions: Hepatic/renal impairment, hypokalemia, hypersensitivity to other triazoles (e.g., itraconazole, terconazole), imidazoles (e.g., butoconazole, ketoconazole). Medications or conditions are known to cause arrhythmias.
Interferes with cytochrome P-450 activity, an enzyme necessary for ergosterol formation.
Therapeutic Effect: Directly damages the fungal membrane, altering its function. Fungistatic.
Pharmacokinetics of Fluconazole
Well absorbed from GI tract. Widely distributed, including to CSF. Protein binding: 11%. Partially metabolized in the liver. Excreted unchanged primarily in the urine. Partially removed by hemodialysis. Half-life: 20–30 hrs (increased in renal impairment).
Lifespan considerations
Pregnancy/Lactation: Secreted in human breast milk. Use caution in breastfeeding females. Children: No age-related precautions were noted. Elderly: Age-related renal impairment may require dosage adjustment.
Interactions of Fluconazole
DRUG: Increases concentration/effect of calcium channel blockers (e.g., amlodipine, nifedipine, verapamil), celecoxib, cyclosporine, midazolam, methadone, NSAIDs (e.g., ibuprofen, ketorolac, naproxen), rifabutin, sirolimus, tacrolimus, theophylline, tofacitinib, zidovudine. May increase concentration/effect, risk of myopathy of HMG-CoA reductase inhibitors (e.g. atorvastatin, simvastatin). HCTZ may increase concentration/effect. Cimetidine, rifampin may decrease concentration/effect. May increase concentration/effect of oral hypoglycemics (e.g., glipizide, glyburide), phenytoin. May further prolong the prothrombin time of warfarin. Quinidine may increase QT prolongation; risk of torsades de pointes. HERBAL: None significant. FOOD: None known. LAB VALUES: May increase serum alkaline phosphatase, bilirubin, ALT, AST.
PO and IV therapy equally effective; IV therapy is recommended for pt intolerant of drug or unable to take orally. Oral suspension stable for 14 days at room temperature or refrigerated.
Usual Dosage
Note: Duration and dose-dependent on location/severity of infection.
PO/IV: ADULTS, ELDERLY: 150 mg once or loading dose: 200–800 mg.
Maintenance dose: 200–800 mg once daily. CHILDREN AND NEONATES:
Loading dose: 6–12 mg/kg. Maintenance dose: 3–12 mg/kg once daily.
Maximum: 600 mg/day.
Subscribe to Our YouTube Channel Please Click Here
Dosage in Renal Impairment
After a loading dose of 400 mg, daily dosage is based on creatinine clearance.
Creatinine Clearance Dosage
Greater than 50 mL/min: 100%
50 mL/min or less: 50%
Dialysis: 50%
CCRT: 400–800 mg as loading dose
CVVH: then 200–800 mg/day
CVVHDF: 400–800 mg as loading dose, then 400–800 mg/day
Exfoliative skin disorders, serious hepatic injury, blood dyscrasias (eosinophilia, thrombocytopenia, anemia, leukopenia) have been reported rarely. May increase risk of QT prolongation, torsades de pointes. Skin disorders including Stevens-Johnson syndrome, toxic epidermal necrolysis may occur.
Nursing considerationsof Fluconazole
Baseline assessment
Obtain CBC, LFT; serum potassium in critically ill pts. Receive full medication history and screen for interactions. Assess areas of infection. Assess infected area.
Intervention/evaluation
Assess for hypersensitivity reaction (chills, fever). Monitor CBC, BMP, LFT. Report rash, itching promptly. Monitor temperature at least daily. Monitor daily pattern of bowel activity, stool consistency. Assess for dizziness; provide
assistance as needed.
Patient/family teaching
• Report dark urine, pale stool, jaundiced skin or sclera of eyes, rash, pruritus.
• Pts with oropharyngeal infections should maintain fastidious oral hygiene.
• Consult a physician before taking any other medication.
No comments:
Post a Comment
please do not enter any spam link in the comment box
No comments:
Post a Comment
please do not enter any spam link in the comment box